954 related articles for article (PubMed ID: 17316925)
1. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
Collaborative Group for Studies with Yellow Fever Vaccine
Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
[TBL] [Abstract][Full Text] [Related]
2. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru.
Belmusto-Worn VE; Sanchez JL; McCarthy K; Nichols R; Bautista CT; Magill AJ; Pastor-Cauna G; Echevarria C; Laguna-Torres VA; Samame BK; Baldeon ME; Burans JP; Olson JG; Bedford P; Kitchener S; Monath TP
Am J Trop Med Hyg; 2005 Feb; 72(2):189-97. PubMed ID: 15741556
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial.
Camacho LA; Freire Mda S; Leal Mda L; Aguiar SG; Nascimento JP; Iguchi T; Lozana Jde A; Farias RH;
Rev Saude Publica; 2004 Oct; 38(5):671-8. PubMed ID: 15499438
[TBL] [Abstract][Full Text] [Related]
5. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
Barrett AD; Teuwen DE
Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559
[TBL] [Abstract][Full Text] [Related]
6. A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old.
Collaborative Group for Studies of Yellow Fever Vaccine
Mem Inst Oswaldo Cruz; 2015 Sep; 110(6):771-80. PubMed ID: 26517656
[TBL] [Abstract][Full Text] [Related]
7. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
[TBL] [Abstract][Full Text] [Related]
8. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial.
Camacho LA; de Aguiar SG; Freire Mda S; Leal Mda L; do Nascimento JP; Iguchi T; Lozana JA; Farias RH;
Rev Saude Publica; 2005 Jun; 39(3):413-20. PubMed ID: 15997317
[TBL] [Abstract][Full Text] [Related]
9. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.
Gaspar LP; Mendes YS; Yamamura AM; Almeida LF; Caride E; Gonçalves RB; Silva JL; Oliveira AC; Galler R; Freire MS
J Virol Methods; 2008 Jun; 150(1-2):57-62. PubMed ID: 18420285
[TBL] [Abstract][Full Text] [Related]
10. Ontogeny of yellow fever 17D vaccine: RNA oligonucleotide fingerprint and monoclonal antibody analyses of vaccines produced world-wide.
Monath TP; Kinney RM; Schlesinger JJ; Brandriss MW; Brès P
J Gen Virol; 1983 Mar; 64 Pt 3():627-37. PubMed ID: 6298349
[TBL] [Abstract][Full Text] [Related]
11. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.
Campi-Azevedo AC; de Araújo-Porto LP; Luiza-Silva M; Batista MA; Martins MA; Sathler-Avelar R; da Silveira-Lemos D; Camacho LA; de Menezes Martins R; de Lourdes de Sousa Maia M; Farias RH; da Silva Freire M; Galler R; Homma A; Ribeiro JG; Lemos JA; Auxiliadora-Martins M; Caldas IR; Elói-Santos SM; Teixeira-Carvalho A; Martins-Filho OA
PLoS One; 2012; 7(12):e49828. PubMed ID: 23251351
[TBL] [Abstract][Full Text] [Related]
12. Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblasts: yields, thermo and genetic stability, attenuation and immunogenicity.
Freire MS; Mann GF; Marchevsky RS; Yamamura AM; Almeida LF; Jabor AV; Malachias JM; Coutinho ES; Galler R
Vaccine; 2005 Mar; 23(19):2501-12. PubMed ID: 15752837
[TBL] [Abstract][Full Text] [Related]
13. Sanger-based sequencing technology for yellow fever vaccine genetic quality control.
Pestana CP; Lawson-Ferreira R; Lessa-Aquino C; Leal MDLF; Freire MDS; Homma A; Medeiros MA
J Virol Methods; 2018 Oct; 260():82-87. PubMed ID: 30009851
[TBL] [Abstract][Full Text] [Related]
14. An inactivated cell-culture vaccine against yellow fever.
Monath TP; Fowler E; Johnson CT; Balser J; Morin MJ; Sisti M; Trent DW
N Engl J Med; 2011 Apr; 364(14):1326-33. PubMed ID: 21470010
[TBL] [Abstract][Full Text] [Related]
15. Antibody response to 17D yellow fever vaccine in Ghanaian infants.
Osei-Kwasi M; Dunyo SK; Koram KA; Afari EA; Odoom JK; Nkrumah FK
Bull World Health Organ; 2001; 79(11):1056-9. PubMed ID: 11731813
[TBL] [Abstract][Full Text] [Related]
16. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil.
Suzano CE; Amaral E; Sato HK; Papaiordanou PM;
Vaccine; 2006 Feb; 24(9):1421-6. PubMed ID: 16236402
[TBL] [Abstract][Full Text] [Related]
17. The 17D-204 and 17DD yellow fever vaccines: an overview of major similarities and subtle differences.
Ferreira CC; Campi-Azevedo AC; Peruhype-Magalhāes V; Costa-Pereira C; Albuquerque CP; Muniz LF; Yokoy de Souza T; Oliveira ACV; Martins-Filho OA; da Mota LMH
Expert Rev Vaccines; 2018 Jan; 17(1):79-90. PubMed ID: 29172832
[TBL] [Abstract][Full Text] [Related]
18. Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination.
Martins MA; Silva ML; Elói-Santos SM; Ribeiro JG; Peruhype-Magalhães V; Marciano AP; Homma A; Kroon EG; Teixeira-Carvalho A; Martins-Filho OA
Vaccine; 2008 Feb; 26(9):1173-84. PubMed ID: 18243433
[TBL] [Abstract][Full Text] [Related]
19. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys.
Marchevsky RS; Freire MS; Coutinho ES; Galler R
Virology; 2003 Nov; 316(1):55-63. PubMed ID: 14599790
[TBL] [Abstract][Full Text] [Related]
20. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.
Poland JD; Calisher CH; Monath TP; Downs WG; Murphy K
Bull World Health Organ; 1981; 59(6):895-900. PubMed ID: 6978196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
